Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation

Transplantation

Volumn 95, Issue 6, 2013, Pages 816-820

  De Vries, Dorottya K ^a   Der Pol, Pieter Van ^a   Van Anken, Gerritje E ^a   Van Gijlswijk, Danielle J ^a   Damman, Jeffrey ^b   Lindeman, Jan H ^a   Reinders, Marlies E J ^a   Schaapherder, Alexander F ^a   Van Kooten, Cees ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Complement; Innate immunity; Ischemia reperfusion injury; Kidney transplantation

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; ARTICLE; CADAVER KIDNEY; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CIRCULATION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REPERFUSION INJURY; ACUTE DISEASE; AGED; ANIMAL; BIOPSY; DONOR; HISTOLOGY; KIDNEY; METABOLISM; METHODOLOGY; MIDDLE AGED; REPERFUSION; STATISTICAL MODEL;

ACUTE DISEASE; ADULT; AGED; ANIMALS; BIOPSY; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; REPERFUSION; REPERFUSION INJURY; TISSUE DONORS;

MLCS; MLOWN;

EID: 84877599866     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827e31c9     Document Type: Article

References (29)

1. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. Tr ansplantation 1997; 63: 968.
2. Yarlagadda SG, Coca SG, Formica RN Jr, et al. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039.
3. Koning OH, Ploeg RJ, van Bockel JH, et al. Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997; 63: 1620.
4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991.
5. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312.
6. Kawana S, Nishiyama S. Serum SC5b-9 (terminal complement complex) level, a sensitive indicator of disease activity in patients with Henoch-Schonlein purpura. Dermatology 1992; 184: 171.
7. Chiu YY, Nisihara RM, Wurzner R, et al. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol 1998; 8: 239.
8. Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23: 381.
9. Zheng X, Zhang X, Feng B, et al. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 2008; 173: 973.
10. de Vries B, Matthijsen RA, Wolfs TG, et al. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003; 75: 375.
11. Park P, Haas M, Cunningham PN, et al. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol 2001; 12: 1383.
12. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363.
13. van der Pol P, Schlagwein N, van Gijlswijk DJ, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant 2012; 12: 877.
14. Baldwin WM III, Samaniego-Picota M, Kasper EK, et al. Complement deposition in early cardiac transplant biopsies is associated with is-chemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894.
15. Yasojima K, Schwab C, McGeer EG, et al. Human heart generates complement proteins that are upregulated and activated after myo-cardial infarction. Circ Res 1998; 83: 860.
16. Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15, 196 patients. J Thorac Cardiovasc Surg 2008; 136: 884.
17. Fattouch K, Bianco G, Speziale G, et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007; 32: 326.
18. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004; 291: 2319.
19. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myo-cardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176.
20. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with An-gioplasty (COMMA) trial. Circulation 2003; 108: 1184.
21. Lazar HL, Bokesch PM, van LF, et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004; 110: II274.
22. Castellano G, Melchiorre R, Loverre A, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion- induced renal damage. Am J Pathol 2010; 176: 1648.
23. Collard CD, Vakeva A, Morrissey MA, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000; 156: 1549.
24. de Vries DK, Lindeman JH, Tsikas D, et al. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am J Transplant 2009; 9: 1574.
25. Collard CD, Montalto MC, Reenstra WR, et al. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001; 159: 1045.
26. Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1Vmechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23: 223.
27. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711.
28. de Vries B, Walter SJ, Peutz-Kootstra CJ, et al. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004; 165: 1677.
29. de Vries DK, Lindeman JH, Ringers J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant 2011; 11: 1064.